CTLA4 and melanoma: Das et al. [65] reported that although anti-CTLA-4 and anti-PD-1 antibodies had no apparent effects on B cells in advanced melanoma patients when administered individually, their combination increased in serum plasmablasts and CXCL13, a marker of GC activation.